Rapid and ultrarapid opioid detoxification techniques

JAMA

Volumn 279, Issue 3, 1998, Pages 229-234

  O'Connor, Patrick G ^a   Kosten, Thomas R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OPIATE;

COST EFFECTIVENESS ANALYSIS; DRUG DEPENDENCE; DRUG DETOXIFICATION; HUMAN; MEDICAL LITERATURE; OPIATE ADDICTION; OUTCOMES RESEARCH; PRIORITY JOURNAL; RELAPSE; REVIEW; TECHNIQUE; WITHDRAWAL SYNDROME;

EID: 0032554055     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.3.229     Document Type: Review

References (49)

1. O'Connor PG, Kosten TR. Management of opioid intoxication and withdrawal. In: Miller N, ed. Principles of Addiction Medicine. Washington, DC: American Society of Addiction Medicine; 1994;chap 5:1-6.
2. Farrell M. Opiate withdrawal. Addiction. 1994;89:1471-1475.
3. Wodak A. Managing illicit drug use: a practical guide. Drugs. 1994;47:446-457.
4. Seivewright NA, Greenwood J. What is important in drug misuse treatment? Lancet. 1996;347:373-376.
5. Dole VP. A medical treatment for diacetylmorphine (heroin) addiction. JAMA. 1965;193:646-650.
6. Gold MS. Opiate addiction and the locus coeruleus: the clinical utility of clonidine, naltrexone, methadone, and buprenorphine. Psychiatr Clin North Am. 1993;16:61-73.
7. Charney DS, Sternberg DE, Kleber HD, et al. The clinical use of clonidine in abrupt withdrawal from methadone. Arch Gen Psychiatry. 1982;38:1273-1277.
8. Resnick RB, Kestenbaum RS, Washton A, Poole D. Naloxone-precipitated withdrawal: a method for rapid induction onto naltrexone. Clinical Pharmacol Ther. 1977;21:409-413.
9. Charney DS, Heninger GR, Kleber HD. The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone. Am J Psychiatry. 1986;143:831-837.
10. Cook CC, Lipsedge MS. The pros and cons of naltrexone detoxification. Br J Hosp Med. 1987;38:79-80.
11. Loimer N, Schmid R, Presslich O, Lenz K. Naloxone treatment for opiate withdrawal syndrome. Br J Psychiatry. 1988;153:851-852.
12. Stephenson J. Experts debate merits of 1-day opiate detoxification under anesthesia. JAMA. 1997;277:363-364.
13. Winick C. Epidemiology. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG, eds. Substance Abuse: A Comprehensive Textbook. 3rd ed. Baltimore, Md: Williams & Wilkins; 1997:10-16.
14. L'Abbe KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med. 1987;107:224-233.
15. Guyatt GH, Sackett DL, Cook DJ, and the Evidence-Based Medicine Working Group. User's guides to the medical literature, II: how to use an article about therapy or prevention, A: are the results of the study valid? JAMA. 1993;270:2598-2601.
16. Guyatt GH, Sackett DL, Cook DJ, and the Evidence-Based Medicine Working Group. User's guides to the medical literature, II: how to use an article about therapy or prevention, B: what were the results and will they help me in caring for patients? JAMA. 1994;271:59-63.
17. Feinstein AR. Clinical Epidemiology: The Architecture of Clinical Research. Philadelphia, Pa: WB Saunders Co; 1985.
18. Riordan CE, Kleber HD. Rapid opiate detoxification with clonidine and naltrexone. Lancet. 1980;1:1079-1080.
19. Masini E, Blandina P, Mannaioni PF, Luciani G. Clonidine and naloxone for rapid opiate detoxification: comparison between treatments. Clin Toxicol. 1981;18:1021-1026.
20. Holman PW. Clonidine and naloxone in ultra-short opiate detoxification. Clin Pharmacy. 1985;4:100-102.
21. Kleber HD, Topazian M, Gaspari J, Riordan CE, Kosten T. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse. 1987;13:1-17.
22. Brewer C, Rezae H, Bailey C. Opioid withdrawal and naltrexone induction in 48-72 hours with minimal drop-out, using a modification of the naltrexone-clonidine technique. Br J Psychiatry. 1988;153:340-343.
23. Vining E, Kosten TR, Kleber HD. Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers. Br J Addict. 1988;83:567-575.
24. O'Connor PG, Waugh ME, Carroll KM, Rounsaville BJ, Diagkogiannis IA, Schottenfeld RS. Primary care-based ambulatory opioid detoxification: the results of a clinical trial. J Gen Intern Med. 1995;10:255-260.
25. Gerra G, Marcato A, Caccavari R, et al. Clonidine and opiate receptor antagonists in the treatment of heroin addiction. J Subst Abuse Treat. 1995;12:35-41.
26. O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ. Three methods of opioid detoxification in a primary care setting: a randomized trial. Ann Intern Med. 1997;127:526-530.
27. Loimer N, Schmid RW, Presslich O, Lenz K. Continuous naloxone administration suppresses opiate withdrawal symptoms in human opiate addicts during detoxification treatment. J Psychiatr Res. 1989;23:81-86.
28. Loimer N, Schmid R, Lenz K, Presslich O, Grunberger J. Acute blocking of naloxone-precipitated opiate withdrawal symptoms by methohexitone. Br J Psychiatry. 1990;157:748-752.
29. Loimer N, Lenz K, Schmid R, Presslich O. Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates. Am J Psychiatry. 1991;148:933-935.
30. Loimer N, Linzmayer L, Schmid R, Grunberger J. Similar efficacy of abrupt and gradual opiate detoxification. Am J Drug Alcohol Abuse. 1991;17:307-312.
31. Loimer N, Hofmann P, Chaudhry H. Ultrashort noninvasive opiate detoxification. Am J Psychiatry. 1993;150:839.
32. Presslich O, Loimer N, Lenz K, Schmid R. Opiate detoxification under general anesthesia by large doses of naloxone. J Toxicol Clin Toxicol. 1989;27:263-270.
33. Legarda JJ, Gossop M. A 24-h inpatient detoxification treatment for heroin addicts: a preliminary investigation. Drug Alcohol Depend. 1994;35:91-93.
34. Seoane A, Carrasco G, Cabre L, et al. Efficacy and safety of two new methods of rapid intravenous detoxification in heroin addicts previously treated without success. Br J Phychiatry. 1997;171:340-345.
35. Mattick RP, Hall W. Are detoxification programmes effective? Lancet. 1996;347:97-100.
36. O'Brien CP, McLellan A. Myths about the treatment of addiction. Lancet. 1996;347:237-240.
37. Rabinowitz J, Cohen H, Tarrasch R, Kotler M. Compliance to naltrexone treatment after ultra-rapid opiate detoxification: an open label naturalistic study. Drug Alcohol Depend. 1997;47:77-86.
38. O'Connor PG, Oliveto AH, Shi JM, et al. A randomized trial of buprenorphine maintenance for treating heroin dependence in a primary care versus a drug treatment setting. J Gen Intern Med. 1997;12(suppl):78.
39. Kosten TR, Kleber HD. Strategies to improve compliance with narcotic antagonists. Am J Drug Alcohol Abuse. 1984;10:249-266.
40. Brown DL. Anesthesia risk: a historical perspective. In: Brown DL, ed. Risks and Outcome in Anesthesia. 2nd ed. Philadelphia, Pa: JB Lippincott Co; 1992:1-35.
41. Warner MA, Shields SE, Chute CG. Major morbidity and mortality within one month of ambulatory surgery and anesthesia. JAMA. 1993;270:1437-1441.
42. San L, Puig M, Bulbena A, Farre M. High risk of ultrashort noninvasive opiate detoxification. Am J of Psychiatry. 1995;152:956.
43. Taft RH. Pulmonary edema following noloxone administration in a patient without heart disease. Anesthesiology. 1983;59:576-577.
44. Andree MA. Sudden death following noloxone administration. Anesth Analg. 1980;59:782-784.
45. Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment. New York, NY: Springer-Verlag Inc; 1991.
46. McLellan AT, Arndt IO, Metzger DS, Woody GE, O'Brien CP. The effects of psychosocial services in substance abuse treatment. JAMA. 1993;269:1953-1959.
47. Kosten TR, McCance E. A review of pharmacotherapies for substance abuse. Am J Addict. 1996;5:58-65.
48. Capone T, Brahen L, Condren R, Kordal N, Melchionda R, Peterson M. Retention and outcome in a narcotic antagonist treatment program. J Clin Psychol. 1986;42:825-833.
49. Gonzalez JP, Brogden RN. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs. 1988;35:192-213.